Fundraising Fox
/People
Sign in

Julie Grant

Investor

General Partner / West Coast at Canaan Partners · Board director at Solstice Oncology · Board director at Day One Biopharmaceuticals · Board director at Nocion Therapeutics

San Francisco Bay Area

Writes $250K – $20M checks · typically $10M

Find your path to Julie

828 people in our graph can introduce you to Julie.

Each arrow is one introduction. Sign up to fill in the first one.

Ask Sam Blackman to introduce you to Julie

You →Sam · together at Day One Biopharmaceuticals (2018–2023) →Julie

Ask Jamie Chen to introduce you to Julie

You →Jamie · together at Chrono Therapeutics →Julie

Ask Sam Okafor to introduce you to Julie

You →Sam · together at Nocion Therapeutics →Julie

Sign up to find every way you can get introduced to Julie

  • Your email: the people you already email who know Julie
  • 2nd- and 3rd-degree connections: people you know who worked, studied or invested with Julie
  • Your LinkedIn: the connections who can make the intro for you

We rank every route by how warm it is, so you raise on warm intros instead of cold emails.

Sign up with GoogleAlready have an account? Log in

About

Julie Grant is an investor at Canaan Partners and a co-founder and former CEO of Day One Biopharmaceuticals, a biotech she incubated at Canaan with Dr. Sam Blackman to develop cancer treatments for children. Day One raised a $60M Series A from Canaan, Atlas Venture, and Access Biotechnology, and focuses on rare-disease drug development in pediatric oncology.

Contact· self-published, not guessed

Invests in

BiotechConsumerDeep TechEnterprise SoftwareFintechHardware

Board director at Solstice Oncology

Intro paths

→

In turn, Julie can intro founders to Solstice Oncology's investors below.

Solstice Oncology's investors · 3

Canaan PartnersStamford · $500K – $20M checks · since 2026ForbionNaarden · since 2026RA CapitalBoston · since 2026

Board director at Day One Biopharmaceuticals

Intro paths

→

In turn, Julie can intro founders to Day One Biopharmaceuticals's investors below.

Day One Biopharmaceuticals's investors · 7

Access BiotechnologyNew York · since 2021Access IndustriesNew York · since 2020Atlas VentureCambridge · $500K – $1M checks · since 2021Canaan PartnersStamford · $500K – $20M checks · since 2021RA CapitalBoston · since 2021The Column GroupSan Francisco · $30M checks · since 2021Viking Global

Board director at Nocion Therapeutics

Intro paths

→

In turn, Julie can intro founders to Nocion Therapeutics's investors below.

Nocion Therapeutics's investors · 7

Canaan PartnersStamford · $500K – $20M checks · since 2025F-Prime CapitalCambridge · $3M – $10M checks · since 2024Lumira VenturesToronto · $1M – $10M checksMission BiocapitalSan Francisco · $500K checks · since 2024Monograph Capital PartnersLondon · since 2025Osage University PartnersBala Cynwyd · since 2024OUP (Osage University Partners)Bala Cynwyd · $1M – $20M checks

Experience

  1. CanaanGeneral Partnercurrent2019 — presentSan Francisco Bay Area
  2. CanaanPartner2016 — 2019Menlo Park and San Francisco
  3. CanaanPrincipal2014 — 2016Menlo Park, CA
  4. CanaanAssociate2013 — 2014Menlo Park
  5. SynthekineBoard Membercurrent2019 — presentPalo Alto, California, United States
  6. Nocion Therapeutics, Inc.Board Membercurrent2018 — presentGreater Boston
  7. Day One BiopharmaceuticalsChair Of The Board Of Directors2020 — 2023
  8. Day One BiopharmaceuticalsCo-Founder and Chief Executive Officer2018 — 2020South San Francisco, California, United States
  9. GlookoBoard Observer2015 — 2019
  10. Biden Cancer InitiativeBoard Member2017 — 2018Washington DC-Baltimore Area
  11. Chrono TherapeuticsBoard Observer2014 — 2018
  12. Protagonist TherapeuticsBoard Member2015 — 2017
  13. CytomX TherapeuticsBoard Observer2013 — 2015
  14. Cellular ResearchSeed Investor and Board Observer2013 — 2015
  15. ALDEA PharmaBoard Observer2013 — 2015
  16. Dermira, Inc.Board Observer2013 — 2014
  17. LABRYS BIOLOGICS, INC.Board Observer2013 — 2014
  18. GenentechMarket Planning Manager - BioOncology New Products Lead2010 — 2011
  19. GenentechMarket Planning Manager - Tarceva2008 — 2010
  20. GenentechBioOncology Project Manager2006 — 2008
  21. GenentechBusiness Development Intern2006
  22. Yale University Office of Cooperative ResearchLicensing Intern2005
  23. Goldman SachsSummer Analyst, Americas Special Situations Group2004

Skills & more

Venture Capital25Start-ups60Product Development10Biotechnology56Business Development39Lifesciences27Medical Devices19Biopharmaceuticals13Strategy26Cross-functional Team Leadership11Product Launch4Product Management4
+8 moreCompetitive AnalysisDrug DevelopmentProduct MarketingOncologyPharmaceutical IndustryMarket ResearchCompetitive IntelligenceProject Management

Languages French

From Julie's professional profile.

Deals · 2

Nocion TherapeuticsBoard seat

via Canaan Partners · filed Mar 2026 · $23M raise

Solstice OncologyBoard seat

via Canaan Partners · filed Mar 2026 · $298.4M raise

Attribution from SEC filings, press coverage, and firm rosters.

Other disclosed investments

Sources: the firm's website · curated public sources · SEC Form D filings.

Colleagues at Canaan Partners

Antonio Lepore
Investor at Canaan Partners
Brendan Dickinson
General Partner at Canaan Partners
Brent Ahrens
General Partner at Canaan Partners
Brenton Ahrens
General Partner at Canaan Partners
Colleen Cuffaro
Partner at Canaan Partners
Dana Malman Warren
Investor at Canaan Partners
Deepak Kamra
General Partner at Canaan Partners
Derek Wu
Associate / East Coast at Canaan Partners

Frequently asked questions

Who is Julie Grant?
Julie Grant is an investor at Canaan Partners and a co-founder and former CEO of Day One Biopharmaceuticals, a biotech she incubated at Canaan with Dr. Sam Blackman to develop cancer treatments for children. Day One raised a $60M Series A from Canaan, Atlas Venture, and Access Biotechnology, and focuses on rare-disease drug development in pediatric oncology.
Where does Julie Grant work?
Julie Grant is General Partner / West Coast at Canaan Partners and Board director at Solstice Oncology and Board director at Day One Biopharmaceuticals and Board director at Nocion Therapeutics.
What does Julie Grant invest in?
Julie Grant invests in Biotech, Consumer, Deep Tech, Enterprise Software, Fintech, Hardware.
What check size does Julie Grant write?
Julie Grant typically writes checks of $250K – $20M.
What boards does Julie Grant sit on?
Julie Grant holds tracked board seats at Day One Biopharmaceuticals, Nocion Therapeutics, Solstice Oncology.
What companies has Julie Grant invested in?
Investments tracked here include Nocion Therapeutics, Protagonist Therapeutics, Cellular Research, Civitas, CytomX Therapeutics, Day One Biopharmaceuticals, Dermira, Labrys Biologics, Nocion, Nocion Therapeutics, Protagonist Therapeutics, Reactive Biosciences Inc., and 5 more.
Where did Julie Grant go to school?
Julie Grant studied at Stanford University Graduate School of Business (MBA); University of Cambridge (MPhil, BioScience Enterprise); Yale University (B.S., Molecular Biophysics and biochemistry).
Does Julie Grant lead rounds?
Yes — Julie Grant has led 2 tracked investments.

Founder mafias

Same school

Shared employers